DuPont de Nemours, Inc.DD
NYSE•Basic Materials•Specialty Chemicals
DuPont de Nemours, Inc. provides technology-based materials and solutions in the United States, Canada, the Asia Pacific, Latin America, Europe, the Middle East, and Africa. It operates through two segments, Healthcare & Water Technologies and Diversified Industrials. The company offers specialty components for medical devices, packaging and garments, and protective suits under the brand TYVEK; provides water filtration and separation solutions, including elements, modules, and systems serving primarily industrial wastewater and energy markets, municipal and desalination applications, and life sciences and specialty sectors. It also offers AMBERLITE ion exchange resins, FILMTEC reverse osmosis and nanofiltration elements, and INGE and ITEGRATEC ultrafiltration modules. In addition, the company offers engineered products and integrated solutions for the non-residential, residential, and repair-and-remodel construction markets, includes TYVEK house wrap, STYROFOAM insulation, and CORIAN solid surface. Further, it engages in the design and production of engineered components, systems, and process solutions used in OEM and operational applications, such as automotive, aerospace, printing, and packaging. Additionally, the company offers Vespel shapes and parts, MOLYKOTE specialty lubricants, BETAFORCE and BETASEAL structural adhesives, and Cyrel flexographic printing plates. The company was formerly known as DowDuPont Inc. and changed its name to DuPont de Nemours, Inc. in June 2019. DuPont de Nemours, Inc. was incorporated in 2015 and is headquartered in Wilmington, Delaware.
DuPont de Nemours, Inc. (DD) reported trailing twelve months revenue of $9.70B as of March 2026, a 20.4% decline year-over-year. Quarterly revenue reached $1.68B, reflecting a contraction in sales.
DuPont de Nemours, Inc. reported a TTM net loss of $29.00M, with quarterly EBITDA of $219.00M. The operating margin contracted from 16.1% to 11.1%, suggesting rising cost pressures or pricing headwinds.
The spread between operating margin (11.1%) and net margin (9.6%) indicates tight cost control with minimal non-operating drag. Net margin has improved from -19.2% a year ago, signaling stronger bottom-line efficiency.
DD trades at a P/S of 1.9x. The price-to-book ratio of 1.3x reflects a moderate premium to book value.
The company generated $130.00M in free cash flow over the trailing twelve months, a 27.5% increase year-over-year, indicating strong cash generation ability. The balance sheet shows $21.45B in total assets with $3.13B in long-term debt against $14.04B in stockholders equity for a debt-to-equity ratio of 0.2, a conservative capital structure. Data based on the most recent quarterly reports.
Competitive analysis based on 21 quarters of fundamental data
Operating margins are positive at ~15.3% on average, but show some variability — pricing power may be sensitive to market conditions.
ROE is low or negative, suggesting limited competitive advantage or capital allocation challenges.
7 of the last 8 quarters generated positive FCF. The company generally funds itself but has occasional cash consumption quarters.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
Data-driven red flags and warnings across 21 quarters
Operating margins declined 8.3% — watch for continued compression, which may signal competitive or cost pressure.
FCF consistently trails net income (avg -0.2x) — earnings may be inflated by non-cash items or aggressive accounting.
D/E ratio is 0.2 — conservative capital structure with low financial risk.
Revenue has softened, declining in 3 quarters. Monitor for further erosion.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Share count is stable — no significant dilution or buyback activity.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation